Search

Attempts to study the effect of blend MnO2 and PANI-MnO2 nanocomposites in enhancing the productivity of an acrylic Pyramid Solar Still (PSS) is carried out. Synthesized nanocomposites assorted with black paint to improve the absorption efficiency. Size of the synthesized MnO2 is found to be 35nm. SEM image infers particles are aggregates with random shape. Thermal analysis if distillate yield confirms the formation of nanocomposite with improved thermal stability of the PANI. Distillate yield is observed around 0.484 litre/0.25m2, 0.568 litre/0.25m2 and 0.615 litre/0.25m2 still without and with MnO2 and PANI-MnO2 nanocomposites. Average efficiency is found to be 23.05%, 26.63% and 28.52% under three modes. Efficiency of the combined performance is amended due to the absorption properties of MnO2 and PANI-MnO2. Performance ratio under three modes are found to be 5.52 %, 6.44 % and 6.93 %. Results concluded that saturation vapour pressure and latent heat also plays a major hole in production of distillate yield.

In this research, using a capability perspective, we first define innovation based, strategic flexibility (ISF) as consisting of three lower-level capabilities- market sensing,resource reconfiguration, and proactiveness; then link it to new-product/innovation outcomes, and develop a new metric of ISF that is input-output based. This metric captures a firm’s realized flexibility in translating market opportunities into innovation output. We then examine the role of CEO ties with marketing and R&D in driving a firm's ISF. Combining survey data of 191 CEOs with objective performance data, we find that (a) ISF is positively influenced by the frequency and duration of the CEO's relationship with the two functional units, but negatively influenced by CEO's relationship closeness, and (b) ISF contributes to future profit growth of firms. We test the robustness of our findings to the potential violation of sequential-ignorability assumption as defined in the causal mediation literature and find the results to be robust. The results provide insights into the role of CEO characteristics in driving innovation, and upper echelon’s contributions to marketing.

During the past quarter-century, digital technologies-based innovations for creating, communicating, and delivering products of value to customers have significantly risen in importance to the competitiveness of firms. Digital technologies-based innovations have been transformational in numerous ways, such as their impact on firms’ marketing behaviors, consumers’ search and buying behaviors, and the structural characteristics of markets and industries. Against this backdrop, this article provides a perspective on the evolution of research and practice in digital product innovations and digital marketing innovations. Specifically, the article focuses on (a) innovations for the greater good in the domain of the former and (b) direct and mediated communications through social media platforms and omnichannel marketing in the domain of the latter. In respect of each of the above, the article provides an overview of the evolution and current state of the field, highlights certain current issues and the trajectory of the field, and proposes directions for future research.

Funding Acknowledgements Type of funding sources: None. Background/Introduction Immune checkpoint inhibitor (ICI) myocarditis is a life-threatening condition characterized by lymphocytic myocardial infiltration[1]. Complete heart block (CHB) occurs in 15% of cases and is often fatal[2-4]. The nature and optimal management of this often-malignant condition is poorly understood[5]. Purpose This case series assesses prognostic factors associated with survival at 90 days among people with ICI myocarditis and CHB. Methods The electronic patient record system was used to identify patients admitted with ICI myocarditis. A two-physician review was used to assess the presence of ICI-associated CHB. Wilcoxon rank sum and Spearman’s rank correlation were used for categorical and quantitative variables respectively. Data was analysed using STATA/IC 16.1. The primary outcome was person-day survival 90 days after presenting symptom onset. Results Six patients were included in the final analysis. Mean survival was 47 person days. All had metastatic disease and presented 15 to 32 days after the first ICI infusion. All had muscle weakness. Other common self-symptoms were shortness of breath (4), blurred vision (4), double vision (3), collapse (3), and leg swelling (1). Proximal myopathy (2), fatigable myopathy (1), ptosis (3), and peripheral oedema (1) were present on examination. Raised troponin T and white blood cell count (WBC) were associated with 90-day survival (see Table 1). Nt-pro BNP, AST, and CK levels were raised in all patients. Two patients were tested for anti-striated muscle antibody titres, and both were strongly positive. Increase in QRS duration compared to baseline ECG was associated with lower survival at 90 days. Only one patient had CHB on admission. Steroid dose, IVIG, and plasmapheresis weren’t associated with survival. One patient declined device therapy. One declined permanent pacemaker (PPM) after insertion of transvenous pacemaker (TVP). Both died within 2 weeks. Three people underwent insertion of a transvenous pacemaker (TVP) followed by PPM insertion (table 2). All three eventually died within 100 days. One person received isoproterenol and immunosuppression as a bridge to PPM and survived. One patient was managed initially with TVP but subsequently declined PPM insertion. TVP removal resulted in CHB recurrence, and they died shortly after discharge. One person declined device therapy and died while receiving comfort care. Lead malfunction was frequent. One patient experienced bradycardia arrest with failure of a TVP lead to capture, while another experienced lead dislodgement. Conclusion CHB secondary to ICI is often fatal. It should be considered in patients presenting with symptoms of myositis, raised troponin and increased QRS duration. Despite a small sample size, this study identifies several prognostic factors which can guide both patients and physicians with decision-making. Larger studies are needed to better understand the role of device therapy in this population.

While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ~one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly (or less frequent) booster vaccine, and as a primary vaccine for pediatric use including in infants.

Although antivirals are important tools to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, effective vaccines are essential to control the current coronavirus disease 2019 (COVID-19) pandemic. Plant-derived virus-like particle (VLP) vaccine candidates have previously demonstrated immunogenicity and efficacy against influenza. Here, we report the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a VLP bearing a SARS-CoV-2 spike protein (CoVLP) vaccine candidate formulated with or without Adjuvant System 03 (AS03) or cytidine-phospho-guanosine (CpG) 1018. Although a single dose of the unadjuvanted CoVLP vaccine candidate stimulated humoral and cell-mediated immune responses, booster immunization (at 28 days after priming) and adjuvant administration significantly improved both responses, with higher immunogenicity and protection provided by the AS03-adjuvanted CoVLP. Fifteen micrograms of CoVLP adjuvanted with AS03 induced a polyfunctional interleukin-2 (IL-2)-driven response and IL-4 expression in CD4 T cells. Animals were challenged by multiple routes (i.e., intratracheal, intranasal, and ocular) with a total viral dose of 106 plaque-forming units of SARS-CoV-2. Lower viral replication in nasal swabs and bronchoalveolar lavage fluid (BALF) as well as fewer SARS-CoV-2-infected cells and immune cell infiltrates in the lungs concomitant with reduced levels of proinflammatory cytokines and chemotactic factors in the BALF were observed in animals immunized with the CoVLP adjuvanted with AS03. No clinical, pathologic, or virologic evidence of vaccine-associated enhanced disease was observed in vaccinated animals. The CoVLP adjuvanted with AS03 was therefore selected for vaccine development and clinical trials.

Natural (Caprine bone) Hydroxyapatite/Phyllanthus acidus and Gallium substituted Hydroxyapatite/Phyllanthus acidus composite powders were successfully synthesized by thermal decomposition method. The synthesized powders were confirmed function group by FTIR and the phase purity, crystalline size through XRD results. The SEM results show that the size of the Hydroxyapatite powders reduced with the substitution of Gallium in the natural Hydroxyapatite composite which leads to the formation of finer powders and uniform surface morphology. Natural Gallium substituted Hydroxyapatite/Phyllanthus acidus composite were successfully achieved to obtained better morphology. Gallium substituted Hydroxyapatite/Phyllanthus acidus shows better antibacterial activity compare to Hydroxyapatite/Phyllanthus acidus composite.

Extraordinary specific breaking of the carbon-sulfur linkage of the thiosemicarbazone moiety from a Schiff base has been watched the blue, bringing about the development of a four coordinated tetra CuII cubane containing triphenyl phosphine and µ3-S as ligands. At the same time, the ketimine group of the Schiff base ligands also got ruptured to regenerate the diketone used for the synthesis of thiosemicarbazone ligand. The synthesized complex was spectrally and structurally investigated. The crystallographic information reveals that the complex is having the shape of a cubane, where as the alternate four corners were occupied by tricoordinated copper and the other corners are by µ3-S respectively. µ3-S behaves as a ligand which is having the binegative site and neutral site to get bonded with the copper as bridging ligand. Antimicrobial and antioxidant efficacy were explored and shows a better results than the controls used.

Every year, large quantities of construction and demolition waste are generated in India, which is a mixture of different grades of concrete. Such waste disposal required an immense amount of land and induced ecological pollution as well. Globally, researchers are trying to substitute coarse aggregate in concrete with recycled aggregate (RA). In the present paper, construction & demolition (C&D) waste was obtained from nearby the Jaypee University of Engineering and Technology, Guna. Where, due to the up-gradation of National Highway-3, a massive amount of building structures is demolished. In this work, a newly invented technique called pre-soaking in mild acetic acid (3%), followed by mechanical grinding using the Los Angeles abrasion machine for various durations was proposed for RA treatment. To assess the quality of RA, basic properties were studied, such as gradation, structure, abrasion value, crushing value, impact value, bulk density, and water absorption. Strength and durability properties of concrete made with RA were also studied. The improvement in RA’s quality after 72 h of pre-soaking in mild acetic acid (3%) followed by 7 min of mechanical grinding in a Los Angeles abrasion machine was observed optimum duration of treatment based on laboratory work. Strength and durability properties were also studied for concrete made with RA with different natural aggregate (NA) replacement levels (NA). The compressive and split tensile strength increased by 17.11% and 14.03%, respectively, in RAC compared to natural aggregate concrete (NAC) at the 100% replacement level. The innovative proposed technique is an effective one to implement in the field to produce RA to meet the construction industry’s demands.

The dynamics of innate and adaptive immunity to infection in infants remain obscure. Here, we used a multi-omics approach to perform a longitudinal analysis of immunity to SARS-CoV-2 infection in infants and young children in the first weeks and months of life by analyzing blood samples collected before, during, and after infection with Omicron and Non-Omicron variants. Infection stimulated robust antibody titers that, unlike in adults, were stably maintained for >300 days. Antigen-specific memory B cell (MCB) responses were durable for 150 days but waned thereafter. Somatic hypermutation of V-genes in MCB accumulated progressively over 9 months. The innate response was characterized by upregulation of activation markers on blood innate cells, and a plasma cytokine profile distinct from that seen in adults, with no inflammatory cytokines, but an early and transient accumulation of chemokines (CXCL10, IL8, IL-18R1, CSF-1, CX3CL1), and type I IFN. The latter was strongly correlated with viral load, and expression of interferon-stimulated genes (ISGs) in myeloid cells measured by single-cell transcriptomics. Consistent with this, single-cell ATAC-seq revealed enhanced accessibility of chromatic loci targeted by interferon regulatory factors (IRFs) and reduced accessibility of AP-1 targeted loci, as well as traces of epigenetic imprinting in monocytes, during convalescence. Together, these data provide the first snapshot of immunity to infection during the initial weeks and months of life.

The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that evade immunity elicited by vaccination has placed an imperative on the development of countermeasures that provide broad protection against SARS-CoV-2 and related sarbecoviruses. Here, we identified extremely potent monoclonal antibodies (mAbs) that neutralized multiple sarbecoviruses from macaques vaccinated with AS03-adjuvanted monovalent subunit vaccines. Longitudinal analysis revealed progressive accumulation of somatic mutation in the immunoglobulin genes of antigen-specific memory B cells (MBCs) for at least 1 year after primary vaccination. Antibodies generated from these antigen-specific MBCs at 5 to 12 months after vaccination displayed greater potency and breadth relative to those identified at 1.4 months. Fifteen of the 338 (about 4.4%) antibodies isolated at 1.4 to 6 months after the primary vaccination showed potency against SARS-CoV-2 BA.1, despite the absence of serum BA.1 neutralization. 25F9 and 20A7 neutralized authentic clade 1 sarbecoviruses (SARS-CoV, WIV-1, SHC014, SARS-CoV-2 D614G, BA.1, and Pangolin-GD) and vesicular stomatitis virus–pseudotyped clade 3 sarbecoviruses (BtKY72 and PRD-0038). 20A7 and 27A12 showed potent neutralization against all SARS-CoV-2 variants and multiple Omicron sublineages, including BA.1, BA.2, BA.3, BA.4/5, BQ.1, BQ.1.1, and XBB. Crystallography studies revealed the molecular basis of broad and potent neutralization through targeting conserved sites within the RBD. Prophylactic protection of 25F9, 20A7, and 27A12 was confirmed in mice, and administration of 25F9 particularly provided complete protection against SARS-CoV-2, BA.1, SARS-CoV, and SHC014 challenge. These data underscore the extremely potent and broad activity of these mAbs against sarbecoviruses.

Purpose To evaluate the long-term effect of subthreshold nanosecond laser (SNL) treatment on progression to late age-related macular degeneration (AMD). Design Observational extension study of a randomized, sham-controlled trial. Participants Two hundred twelve participants with bilateral large drusen. Methods The Laser Intervention in the Early Stages of AMD (LEAD) study was a 36-month trial where participants were randomized to receive SNL or sham treatment in 1 eye at 6-monthly intervals up to 30 months. After the completion of the LEAD study, the 2 largest recruiting sites offered remaining participants an opportunity to enroll in a 24-month observational extension study. This study thus examined all participants from these 2 sites who were enrolled in the LEAD study at baseline, including the additional observational data. Main Outcome Measures Time to develop late AMD, defined on multimodal imaging, between those randomized the SNL or sham treatment. Results Overall, no significant difference was found in the rate of progression over a 60-month period in those randomized to the SNL compared with the sham group (adjusted hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.36–1.09; P = 0.098), similar to the findings at 36 months in the LEAD Study. However, evidence of treatment effect modification continued to emerge based on the coexistence of reticular pseudodrusen (RPD; P = 0.007, adjusted interaction). Namely, progression was slowed significantly with SNL treatment for those without coexistent RPD (adjusted HR, 0.34; 95% CI, 0.16–0.71; P = 0.004), but it was not significantly different for those with RPD (adjusted HR, 1.81; 95% CI, 0.67–4.88; P = 0.239). Conclusions A 24-month observational extension study to the LEAD Study confirmed that SNL treatment did not significantly reduce the overall rate of progression to late AMD in a cohort with intermediate AMD. However, the persistence of a potential beneficial treatment effect in those without coexistent RPD over a longer follow-up duration of an additional 24 months without additional treatment is encouraging. These findings provide further justification for future trials to examine the potential value of SNL treatment for slowing progression in intermediate AMD.

Waning immunity to vaccination represents a major challenge in vaccinology. Whether booster vaccination improves the durability of immune responses is unknown. Here we show, using a cohort of 55 adult vaccinees who received the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine against SARS-CoV-2, that a booster (i.e., 3rdimmunization) dose at 6 - 10 months increased the half-life of serum neutralizing antibody (nAb) titers to 76 days from 56 - 66 days estimated after the primary two-dose vaccination series. A second booster dose (i.e., 4thimmunization) more than a year after the primary vaccination increased the half-life further to 88 days. However, despite this modestly improved durability in nAb responses against the Wuhan strain, there was a loss in neutralization capacity against Omicron subvariants, especially the recently emerged variants, BA.2.75.2 and BQ.1.1 (35 and 50-fold drop in titers respectively, relative to the ancestral (WA.1) strain. While only 55 – 65% of participants demonstrated a detectable nAb titer against the newer variants after the booster (3rddose), the response declined to below the detection limit in almost all individuals by 6 months. Notably, even against BA.1 and BA.5, the titers declined rapidly in a third of the vaccinees and were below the detection limit at 6 months. In contrast, booster vaccination induced antigen-specific memory B and T cells that persisted for at least 6 months. Collectively, our data show that the durability of immune responses improves following subsequent booster immunizations; however, the emergence of immune evasive variants reduces the effectiveness of booster doses in preventing infection.

Synthesis of nanoparticles from plant extract is a very simple reliable, rapid, affordable and un-hazardous technique. In the present exploration, gold nanoparticles (Au NPs) were rapidly synthesized using seed extract of Abrus precatorius. The prepared nanomaterials were systematically proved by FTIR, UV–Visible, Powder-XRD, SEM, EDAX and TEM analyses. The formation of Au NPs was primarily identified by the colour change from yellow to purple within 5 min and which showed a surface Plasmon peak around 535 nm. The dimension of the gold nanoparticles was found to be in the range of 10–20 nm. The particles were poly-dispersed with a triangular, spherical and hexagonal shape. The gold nanoparticles were used to degrade the antibiotic drug ciprofloxacin (CIP) with an efficiency of above 95%. Moreover, the bio-synthesized gold nanoparticles had been assessed for their in-vitro cytotoxic activity on human breast cancer cells (MCF-7) lines. The colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to evaluate the Inhibitory Concentration (IC50) value. The IC50 value is 37 ± 1.5 µg/mL. In future, this can be used for breast cancer therapy.

The emergency use authorization of two mRNA vaccines in less than a year from the emergence of SARS-CoV-2 represents a landmark in vaccinology1,2. Yet, how mRNA vaccines stimulate the immune system to elicit protective immune responses is unknown. Here we used a systems vaccinology approach to comprehensively profile the innate and adaptive immune responses of 56 healthy volunteers who were vaccinated with the Pfizer–BioNTech mRNA vaccine (BNT162b2). Vaccination resulted in the robust production of neutralizing antibodies against the wild-type SARS-CoV-2 (derived from 2019-nCOV/USA_WA1/2020) and, to a lesser extent, the B.1.351 strain, as well as significant increases in antigen-specific polyfunctional CD4 and CD8 T cells after the second dose. Booster vaccination stimulated a notably enhanced innate immune response as compared to primary vaccination, evidenced by (1) a greater frequency of CD14+CD16+ inflammatory monocytes; (2) a higher concentration of plasma IFNγ; and (3) a transcriptional signature of innate antiviral immunity. Consistent with these observations, our single-cell transcriptomics analysis demonstrated an approximately 100-fold increase in the frequency of a myeloid cell cluster enriched in interferon-response transcription factors and reduced in AP-1 transcription factors, after secondary immunization. Finally, we identified distinct innate pathways associated with CD8 T cell and neutralizing antibody responses, and show that a monocyte-related signature correlates with the neutralizing antibody response against the B.1.351 variant. Collectively, these data provide insights into the immune responses induced by mRNA vaccination and demonstrate its capacity to prime the innate immune system to mount a more potent response after booster immunization. Profiling the immune responses of 56 volunteers vaccinated with BNT162b2 reveals how this mRNA vaccine primes the innate immune system to mount a potent response to SARS-CoV-2 after booster immunization.

Substantial waning of antibody responses to the Pfizer-BioNTech mRNA vaccine 6 months after the second vaccination.

Despite the remarkable efficacy of COVID-19 vaccines, waning immunity and the emergence of SARS-CoV-2 variants such as Omicron represents a global health challenge. Here, we present data from a study in nonhuman primates demonstrating durable protection against the Omicron BA.1 variant induced by a subunit SARS-CoV-2 vaccine comprising the receptor binding domain of the ancestral strain (RBD-Wu) on the I53-50 nanoparticle adjuvanted with AS03, which was recently authorized for use in individuals 18 years or older. Vaccination induced neutralizing antibody (nAb) titers that were maintained at high concentrations for at least 1 year after two doses, with a pseudovirus nAb geometric mean titer (GMT) of 1978 and a live virus nAb GMT of 1331 against the ancestral strain but not against the Omicron BA.1 variant. However, a booster dose at 6 to 12 months with RBD-Wu or RBD-β (RBD from the Beta variant) displayed on I53-50 elicited high neutralizing titers against the ancestral and Omicron variants. In addition, we observed persistent neutralization titers against a panel of sarbecoviruses, including SARS-CoV. Furthermore, there were substantial and persistent memory T and B cell responses reactive to Beta and Omicron variants. Vaccination resulted in protection against Omicron infection in the lung and suppression of viral burden in the nares at 6 weeks after the final booster immunization. Even at 6 months after vaccination, we observed protection in the lung and rapid control of virus in the nares. These results highlight the durable and cross-protective immunity elicited by the AS03-adjuvanted RBD-I53-50 nanoparticle vaccine.

The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative1. Here we demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain displayed on an I53-50 protein nanoparticle scaffold (hereafter designated RBD-NP), to stimulate robust and durable neutralizing-antibody responses and protection against SARS-CoV-2 in rhesus macaques. We evaluated five adjuvants including Essai O/W 1849101, a squalene-in-water emulsion; AS03, an α-tocopherol-containing oil-in-water emulsion; AS37, a Toll-like receptor 7 (TLR7) agonist adsorbed to alum; CpG1018-alum, a TLR9 agonist formulated in alum; and alum. RBD-NP immunization with AS03, CpG1018-alum, AS37 or alum induced substantial neutralizing-antibody and CD4 T cell responses, and conferred protection against SARS-CoV-2 infection in the pharynges, nares and bronchoalveolar lavage. The neutralizing-antibody response to live virus was maintained up to 180 days after vaccination with RBD-NP in AS03 (RBD-NP-AS03), and correlated with protection from infection. RBD-NP immunization cross-neutralized the B.1.1.7 SARS-CoV-2 variant efficiently but showed a reduced response against the B.1.351 variant. RBD-NP-AS03 produced a 4.5-fold reduction in neutralization of B.1.351 whereas the group immunized with RBD-NP-AS37 produced a 16-fold reduction in neutralization of B.1.351, suggesting differences in the breadth of the neutralizing-antibody response induced by these adjuvants. Furthermore, RBD-NP-AS03 was as immunogenic as a prefusion-stabilized spike immunogen (HexaPro) with AS03 adjuvant. These data highlight the efficacy of the adjuvanted RBD-NP vaccine in promoting protective immunity against SARS-CoV-2 and have led to phase I/II clinical trials of this vaccine (NCT04742738 and NCT04750343).

In this present study, a coupled experimental and density functional theory (DFT) studies of organic nonlinear optical (NLO) material, 4-aminobenzenesulfonic acid (4AB), is reported. By slow evaporation method the optical quality, single crystals of 4AB were developed under aqueous medium condition. Single-crystal XRD analysis reveals the crystalline nature of 4AB crystal; the 4AB crystal structure is in the orthorhombic system with noncentrosymmetric (NCS), Pca21, space group. The morphology of developed crystal has been indexed and showed a major facet of the crystal as (002). The molecular construction of 4AB has been well established using 13C and 1H NMR spectroscopic studies. FTIR and FT-RAMAN were found out to be the corresponding vibrational modes of 4AB. Linear optical studies of grown crystal allow near-UV cut-off wavelength range at 261 nm with good optical transparency in the visible and near-IR region and exhibited ultraviolet wavelength emission. Thermal analysis revealed a high thermal stability value of 288 °C for 4AB crystal. Moreover, dielectric and photoconductivity investigations were accomplished efficiently and revealed low dielectric constant and positive photoconducting nature, respectively. The molecular structure of 4AB was optimized at the B3LYP/cc-pVTZ basis set using density functional theory (DFT). The intermolecular hydrogen bond (N1–H1···O1) formation was confirmed by the Mulliken atomic charge distribution analysis and molecular electrostatic potential map analysis. Frontier molecular orbitals (FMOs) evidenced the lower energy gap for the 4AB molecule. Besides NLO properties, the dipole moment (µ0), polarizability (α) and first-order hyperpolarizability (β) were measured for the optimized 4AB molecule.

Traditional drilling is still not appropriate for working with Inconel625 and Inconel718 alloys, since such metals become hard to remove substances. The aim of this article is really to evaluate the two separate metals from empirical data of the micro electrochemical machining (μ-ECM) process on overcut. The overcut was most much a concern when alloys were extracted during machining. Unconventional scientific data is derived from studies unless the authors are using the same instruments for testing the same process variables. Those process variables are chosen for evaluation, such as the volts, the chloride concentration as well as the feed rate of stainless-steel electrodes. Apart from the material removal rate and surface roughness, the overcut is one of the important response variables of μ-ECM. The best possible outcome of an overcut value of 0.021 mm has achieved by Inconel718 alloy. The effects of the overcut on Inconel alloys are compared.